Study: Weight-Loss Drugs Slow Aging

New research published in Nature Communications indicates that GLP-1 agonist medications, such as semaglutide (the active ingredient in Ozempic and Wegovy), may offer a new benefit: slowing biological aging. A 32-week randomized, placebo-controlled trial involving 108 adults with HIV found that semaglutide slowed the pace of biological aging by 9%.

Participants who received semaglutide showed a pattern of slower biological aging, particularly in areas like the blood, brain, heart, kidney, and liver, as well as overall metabolic measures. Experts suggest this effect may be due to semaglutide's ability to reduce inflammation, a factor strongly linked to accelerated aging and various chronic diseases.

While these findings are promising, researchers emphasize that more studies are needed to determine if GLP-1s can be used as gerotherapeutics (drugs designed to slow aging) in the general population. Current research has primarily focused on individuals with existing health conditions like type 2 diabetes, obesity, or HIV, who often have higher baseline inflammation.

Further investigation is crucial to understand if the observed benefits are independent of weight loss, which itself can contribute to reduced inflammation and improved health outcomes. The long-term implications of GLP-1 medications on longevity remain an active area of scientific inquiry.